机译:使用T1减法定量的容积反应预测卡波替尼单药治疗复发性胶质母细胞瘤的长期生存获益
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Exelixis, San Francisco, CA USA;
Exelixis, San Francisco, CA USA;
Exelixis, San Francisco, CA USA;
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA 90095 USA;
Univ Pittsburgh, Med Ctr, Dept Neurol & Med, Pittsburgh, PA USA;
Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA;
Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA;
Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA;
Univ Virginia Hlth Syst, Neurooncol Ctr, Charlottesville, VA USA;
Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Neurol, Seattle, WA 98195 USA;
Henry Ford Hlth Syst, Detroit, MI USA;
Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA;
Exelixis, San Francisco, CA USA;
Exelixis, San Francisco, CA USA;
Exelixis, San Francisco, CA USA;
Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA;
Univ Calif Los Angeles, David Geffen Sch Med, Neurooncol Program, Los Angeles, CA 90095 USA;
cabozantinib; GBM; XL184; recurrent glioblastoma; T1 subtraction;
机译:扩散MRI表型预测复发性胶质母细胞瘤中抗VEGF单药治疗的总体生存获益
机译:重新评估肿瘤进展的影像学定义:灌注MR I量化复发性胶质母细胞瘤的肿瘤分数,假进展和放射坏死以预测存活率
机译:后化学大规模体积反应预测了用辐射,替莫唑胺和Bevacizumab或安慰剂治疗的新诊断胶质母细胞瘤的存活
机译:MRI扫描的深层放射学特征可预测复发性胶质母细胞瘤的生存结果
机译:使用新的和长期多级远程感测数据来检测反复火灾,并量化其与印度尼西亚泥炭地区的土地覆盖/用途的关系=反复消防分析及其与覆盖/土地使用变化的关系
机译:使用T1减法定量的容积反应预测卡波替尼单药治疗复发性胶质母细胞瘤的长期生存获益
机译:对比T1加权MRI预处理获得的几何测量结果可预测贝伐单抗在胶质母细胞瘤患者中的生存获益